Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors. The First Part of the Study is Completed and the Expansion Study is Ongoing (Reference Inclusion/Exclusion Criteria)

Trial Profile

A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors. The First Part of the Study is Completed and the Expansion Study is Ongoing (Reference Inclusion/Exclusion Criteria)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclopirox phosphoryloxymethyl ester (Primary)
  • Indications Bladder cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors CicloMed
  • Most Recent Events

    • 22 Nov 2019 Planned End Date changed from 31 Jul 2019 to 31 May 2020.
    • 22 Nov 2019 Planned primary completion date changed from 31 Jul 2019 to 31 May 2020.
    • 31 May 2019 Results assessing the phamacokinetics of ciclopirox prodrug for the treatment of bladder cancer, in animals and humans, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top